Healio Minute

In this edition, we bring you a deep dive on a collaboration that aims to accelerate better treatments for pediatric cancers. Read the full coverage here:

Collaboration aims to 'truly accelerate better treatments' for pediatric cancers

References:

Dharia NV, et al. Nat Med. 2021;doi:10.1038/s41588-021-00819-w.

In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more.

Read the full coverage here:

Tumor mutational burden may be linked to immunotherapy response in advanced cancers

Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC

Phase 3 study of lung cancer regimen designed to be a model for increasing trial diversity

Smoking cessation before lung cancer diagnosis significantly reduces excess mortality risk

Pembrolizumab active in diffuse malignant peritoneal mesothelioma

References:

Aggarwal C, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11181.

Lu S, et al. Abstract 425126. Presented at: ASCO Plenary Series: April 2023 Session; April 20, 2023.

Marmarelis ME, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2526.

Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients (NCI press release). Published April 12, 2023. Accessed April 12, 2023.

Wang X, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11966.

In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more. Read the full coverage here:

Addition of immunotherapy to chemotherapy improves survival rates of infants with leukemia

Extreme poverty linked to nearly twofold higher risk for relapse among children with ALL

FDA approves allogeneic cell therapy Omisirge for patients with blood cancers

Vaping linked to cancer-related cognitive impairment among young adult cancer survivors

Intervention reduces financial toxicity among people with blood cancers

References:

Healio Interview

Ng DQ, et al. JCO Oncol Pract. 2023;doi:10.1200/op.22.00458.

Press Release

van der Sluis IM, et al. N Eng J Med. 2023;doi:10.1056/NEJMoa2214171.

Wadhwa A, et al. Blood. 2023;doi:10.1182/blood.2023019631.

In this edition, trichloroethylene may be 'invisible' cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.

Read the full coverage here:

Trichloroethylene may be 'invisible and highly preventable' cause of Parkinson's disease

DEA petitioned to de-schedule dual orexin receptor antagonist insomnia medications

Ravulizumab reduces clinical deterioration in patients with generalized myasthenia gravis

FDA places partial clinical hold on initiation of new patients in evobrutinib study

FDA advisory committees rule in favor of Rexulti for agitation associated with Alzheimer's

References:

Dorsey ER, et al. J Parkinsons Dis. 2023;doi:10.3233?JPD-225047.

Mantegazza R, et al. Poster 148: Ravulizumab reduces clinical deteriorations in patients with generalized myasthenia gravis: Results from the CHAMPION MG study. Presented at: Muscular Dystrophy Association Clinical & Scientific Conference; March 19-22, 2023; Dallas.

Press Release

Press Release

Press Release

In this edition, elevated cardiotoxicity risk for Black patients after chemotherapy; CV risk factor disparities in childhood cancer survivors; neural network helps identify potential targets for cancer drugs and more. Read the full coverage here:

Black patients may be at elevated cardiotoxicity, HF risk after chemotherapy

CV risk factor disparities in childhood cancer survivors similar to general population

Neural network helps identify many more potential targets for cancer drugs

Blood or marrow transplant survivors at high risk for malignant neoplasms in the GI tract

Optimizing CV health behaviors may lower risk for CVD and cancer

References:

Gebeyehu W, et al. Original Research Abstract 56. Presented at: American College of Cardiology's Advancing the Cardiovascular Care of the Oncology Patient conference; April 14-16, 2023; Washington, D.C. (hybrid meeting).

McDonald A, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.6569.

Meller A, et al. Nat Commun. 2023;doi:10.1038/s41467-023-36699-3.

Noyd DH, et al. JACC CardioOncol. 2023;doi:10.1016/j.jaccao.2023.01.011.

van Sloten T, et al. JACC CardioOncol. 2023;doi:10.1016/j.jaccao.2022.11.015.

In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more. Read the full coverage here:

DNA sequencing could identify patients with AML at high risk for relapse after HSCT

Review highlights major advances, continuing challenges in chronic lymphocytic leukemia

FDA advisory panel backs polatuzumab vedotin-piiq benefit-risk profile in first-line DLBCL

CAR T cells improve quality of life for majority of recipients

Community physicians play essential role in long-term care after CAR-T

References:

Dillon LW, et al. JAMA. 2023;doi:10.1001/jama.2023.1363.

Healio Interviews

Johnson PC, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2022009117.

March 9, 2023 meeting of the Oncologic Drugs Advisory Committee (ODAC). Available at: https://www.youtube.com/watch?v=zCf87ABhqpU. Accessed March 9, 2023.

Shadman M. JAMA. 2023;doi:10.1001/jama.2023.1946.

In this edition, 'paradigm shift' in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.

Read the full coverage here:

Study reveals 'paradigm shift' in non-small cell lung cancer during past decade

Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer

Amivantamab-vmjw shows durable activity in subgroup of patients with advanced NSCLC

Patients with small cell lung cancer have 'real choice' in radiotherapy regimen

Pembrolizumab regimen extends OS in advanced malignant pleural mesothelioma

References:

Bogart J, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.01359.

Chi SA, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2002.

Press Release

Press Release

Press Release

In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more. Read the full coverage here:

Optimal antibiotics timing 'likely differs' among inpatients with cancer, neutropenic fever

Inflammation levels linked to survival in acute myeloid leukemia

Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer

Menin inhibitor produces high response rates in certain acute leukemia subtypes

Tisa-cel CAR-T reinfusion lacks durability for younger patients with B-cell ALL

References:

Chow EJ, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02423.

Issa GC, et al. Nature. 2023;doi:10.1038/s41586-023-05812-3.

Krupski C, et al. Abstract LBA4. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.

Lasry A, et al. Nat Cancer. 2022;doi:10.1038/s43018-022-00480-0. Villars J, et al. Am J Med Qual. 2023;doi:10.1097/JMQ.0000000000000093.

In this edition, FDA clears lab blood test for evaluating concussion, marriage linked to lower risk for dementia, FDA approves nasal spray for migraine in adults and more.

Read the full coverage here:

FDA clears lab blood test for evaluating concussion

Marriage linked to lower risk for dementia, mild cognitive impairment

FDA approves nasal spray for migraine in adults

Noninvasive device for treating tinnitus receives FDA de novo approval

Differences in fighter pilots' brain connectivity may have implications for space travel

References:

Press Release

Press Release

Press Release

Radstake WE, et al. Front Physiol. 2023;doi:10.3389/fphys.2023.1082166.

Skirbekk V, et al. J Aging Health. 2023;doi:10.1177/08982643221131926.

In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more. Read the full coverage here:

Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome

Ponatinib 'should be considered a standard of care' for newly diagnosed Ph+ALL

Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML

Living along US-Mexico border linked to higher risk for death among children with leukemia

Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup

References:

Castellanos MI, et al. Cancer. 2023;doi:10.1002/cncr.34636.

Gyurkocza B, et al. Abstract LBA3. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.

Jabbour E, et al. Abstract 398868. Presented at: ASCO Plenary Series: February 2023 Session; Feb. 15, 2023.

Muffly L, et al. Abstract 86. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.

Press Release